|
Dr. Jean Nichols is a biopharmaceutical industry executive with operating, technical, development, general management and fundraising experience. She was responsible for development of ONTAK�, a drug to treat lymphoma and leukemia, from concept to market, directing all product development activities, manufacturing, clinical trials and regulatory affairs. Her research experience includes infectious diseases, biochemistry, molecular genetics, drug delivery and diagnostics. Dr. Nichol's previous positions include President and Chief Scientific Officer of Seragen, Inc., Managing Director and Chief Operating Officer of StoneGate Partners, LLC, and most recently as a consultant specializing in strategic positioning and execution of product development programs for biopharmaceutical companies by providing senior management or advisory services. Dr. Nichols has been involved in raising more than $250 million from private investors, venture capitalists, initial and secondary public offerings, corporate partnerships and a merger. Dr. Nichols received both her B.S. in Biology and Ph.D. in Bacteriology and Immunology from the University of North Carolina at Chapel Hill. She completed her postdoctoral training at Harvard Medical School and served as a member of junior faculty. Dr. Nichols is an inventor on five patents and has authored 40 articles on infectious diseases and pre-clinical and clinical studies in the field of fusion proteins. | 